Safety and Effectiveness of Orbera365™ Intragastric Balloon System
← catalyst calendarNCT07062094 · readout in 597 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
4
Countries
Czechia, Spain, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-07 | actual | When the study began enrolling |
| Primary completion | 2028-04-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Intervention
- Device: Intragastric Balloon
Primary outcomes
what the primary-completion date above is the date OFRate of Subjects with Serious Adverse Events
measured Up to 12 months
Rate of Treatment Completers
measured Up to 12 months
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed